Article Text

PDF
GW24-e2490 Effects of Valsartan on No-Reflow after Myocardial Ischemia Reperfusion in Rats
  1. Ma Qing-Hua,
  2. Zhang Ying-Jie
  1. Department of Cardiology, The First Affiliated Hospital of Liaoning Medical University

Abstract

Objectives to evaluate the effects of valsartan on myocardial no-reflow and its probable mechanism in signal transduction pathway.

Methods Fifty-six male SD rats were randomly assigned to four groups: shame group, ischaemia and reperfusion group, valsartan group (valsartan 10mg/kg) and valsartan + LY294002 group (valsartan 10mg/kg, LY294002 0.3mg/kg). All rats, except for those in shame group, received occlusion of left anterior descending artery (LAD) for 60 minutes followed by 120 minutes of reperfusion. Valsartan (15 mg/kg) intravenous administration 15 minutes before reperfusion, and LY294002 (0.3 mg/kg ) intravenous administration 5 minutes before reperfusion. Different myocardium regions of ischaemia, no- reflow and infarction were recognised and assessed according to Evans blue dye, thioflavin S fluorescent dye and triphenyltetrazolium chloride (TTC) staining techniques, respectively. Serum CK- MB were detected after experiment. The expression of p-akt, akt, p-eNOS and eNOS was determined by western blotting.

Results Valsartan significantly elevated the expression of p-akt and p-eNOS, reduced CK-MB activity, and reduced the no-reflow (31.26 ± 2.83 vs 21.60 ± 3.29, P<0.01) and necrosis areas (40.16 ± 4.19% vs 27.93 ± 4.57%, P<0.01). However, these effects were reversed by LY294002.

Conclusions Valsartan can reduce the area of myocardial no-reflow after ischaemia-reperfusion. This beneficial effect is dependant on PI3K-akt-eNOS signal transduction pathway.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.